
Definium Therapeutics rose 166.0% from $11.34 to $30.16, ahead of the S&P 500's +11.2%. Its worst day was Nov 2 (−10.6%), and its low came Nov 21 at $10.68.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Definium Therapeutics closed at its lowest level of the year, 5.8% below where the year started.
−1.8% · S&P 500 +1.0%
EPS of $-0.50 missed the $-0.47 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
+0.9% · S&P 500 −0.5%
EPS of $-0.71 missed the $-0.49 estimate on $0.00 revenue.
−5.0% · S&P 500 +0.8%
Definium Therapeutics shares rose 49.8%, while the S&P 500 fell 0.3%.
+49.8%, the year's best day, on 20M shares, the year's heaviest volume · S&P 500 −0.3%
Definium Therapeutics closed at its highest level of the year, 327.2% above where the year started.
+6.9% · S&P 500 +0.8%
EPS of $-1.44 missed the $-0.56 estimate on $0.00 revenue.
0.0% · S&P 500 +0.6%
EPS of $-0.46 beat the $-0.56 estimate on $0.00 revenue.
−2.1% · S&P 500 −0.4%
Where it ended: a close of $30.16 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.50).
Nothing in the past 12 months.
All DFTX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DFTX and SPY from Benzinga historical bars. Not investment advice.